Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effectsPeter A. McSweeney, Rainer Storb, Dietger Niederwieser et al.|Blood|2001Cited by 1.4k
Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaKeith Sullivan, Daniel E. Furst, Julia Goldstein et al.|New England Journal of Medicine|2018Cited by 584
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic MalignanciesMohamed L. Sorror, Rainer Storb, Brenda M. Sandmaier et al.|JAMA|2011Cited by 320
CD34 cell dose in granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen–identical sibling transplantationJan Maciej Zaucha, Beverly Torok‐Storb, Theodore A. Gooley et al.|Blood|2001Cited by 227
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell TransplantationRainer Storb, Brenda M. Sandmaier, Boglarka Gyurkocza et al.|Journal of Clinical Oncology|2013Cited by 212